{"classes":[{"categories":[{"measurements":[{"comment":"Not observed as less than 50% of patients had a worsening of ACR response.","groupId":"OG000","lowerLimit":"171.0","upperLimit":"NA","value":"NA"},{"groupId":"OG001","lowerLimit":"85.0","upperLimit":"281.0","value":"141.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"50"}],"units":"Participants"}],"description":"Kaplan Meier estimate of the time in days to the probability of worsening of the ACR response.\n\nACR response is determined by the following items:\n\n1. Physician's global assessment of disease activity\n2. CHAQ-patient's overall wellbeing\n3. CHAQ-Functional ability\n4. Number of joints with active arthritis\n5. Number of joints with limitation of motion\n6. C-Reactive Protein.\n7. No intermittent fever in the preceding week","dispersionType":"95% Confidence Interval","groups":[{"description":"In Part I participants received open label 4 mg/kg canakinumab subcutaneous injection every 4 weeks for up to 32 weeks. For the first 8 weeks Part Ia (4 weeks) and Ib (4 weeks) patients maintained a stable oral steroid dose (prednisone or equivalent) followed by Ic an up to 20 week steroid tapering period and then Id a 4 week stable steroid dose period. Participants were then randomized to receive either 4 mg/kg canakinumab subcutaneous injection or Placebo comparator in Part II and remained on the stable oral steroid dose for 24 weeks. At 24 weeks in Part II participants with a \\>0.2 mg/kg and ≤ 0.5 mg/kg and no flare could restart steroid tapering. If the steroid dose was ≤ 0.2 mg/kg participants continued to maintain their current dose for the remainder of Part II.","id":"OG000","title":"Canakinumab"},{"description":"Participants in Part II received placebo matching canakinumab subcutaneous injection every 4 weeks. At 24 weeks in Part II participants with a \\>0.2 mg/kg and ≤0.5 mg/kg and no flare could restart steroid tapering. If the steroid dose was ≤0.2 mg/kg participants continued to maintain their current dose for the remainder of Part II.","id":"OG001","title":"Placebo"}],"paramType":"MEDIAN","populationDescription":"Full Analysis Set Part II","reportingStatus":"POSTED","timeFrame":"Part II was event driven. The study was stopped when the required number of 37 flares had occurred (88 weeks)","title":"Part II: Survival Analysis of Time to a Worsening in American College of Rheumatology (ACR) Response","type":"SECONDARY","unitOfMeasure":"Days"}